Our mission is to be the leading provider of equity research in healthcare and life sciences

We produce institutional­ quality equity research on small/mid­cap healthcare and life sciences companies, making it available to all investors wherever they are based. Our goal is to bring exciting investment ideas to investors, and to assist companies in achieving their objectives.



Research Clients



Reports published



Readers in database

$3m new investment from a new US institutional investor, follows hot on the heels of @MereoBioPharma‘s $5m convertible equity financing with @Novartis & up to $28m securities purchase agreement with Aspire Capital agreed earlier this month $MPH.L $MREO

China approval & launch of #surufatinib, @HChiMed’s first wholly owned drug, is on track for late-2020.

We revisit the data & prospects in our $HCM Update note: A wealth of opportunity for surufatinib.

Read more at: https://t.co/WrQb4WeQhK

ADS offering raises $110m; proceeds will progress @HChiMed's broad pipeline of targeted #cancer & #autoimmune disease therapies, & expand commercial infrastructure ahead of potential late-2020 China launch of its 1st wholly-owned asset #surufatinib $HCM


Face to face meeting with FDA confirms requirements for de novo submission of $AGL.L @Parsortix system for use in metastatic #breastcancer

Submission expected Q1 CY20, with prospect of FDA clearance in Q3 CY20


Early stop of SANET-p Phase III after +ve interim analysis. Likely #surufatinib China NDA filing (2nd indication) in 2020 & potentially unique position as effective therapy across the NET (#neuroendcrinetumours) spectrum.
Read more on @HChiMed $HCM at: https://t.co/WrQb4WeQhK

#FuturaMedical £3.25m fund raise extends its cash runway, on current plans, to end-2020. Planned FDA meeting (possibly Q120) will shed further light on next steps for #DermaSys in #erectiledysfunction $FUM

Subscribe to our research

Please sign up here to be added to our distribution database